Federal Register Notice FDA has determined the regulatory review period for Sucampo AG’s Amitiza is 2,197 days for the extension of a patent which claims the human drug product. Amitiza (lubiprostone) is indicated for treating chronic idiopathic constipation in the adult population. To view this notice, click here.
